Products

Through the application of its proprietary SonoTran^® Platform technology, OxSonics^® is developing a pipeline of enhanced therapies. SonoTran has the potential to be applied to almost any anti-cancer agent and can be used across the majority of the most challenging solid tumour cancers.

Pipeline

OxSonics is developing a pipeline of differentiated, next generation therapies with applicability across a broad range of solid tumour oncology indications.

Through both in-house development and strategic partnerships our oncology programmes aim to produce high value yet cost effective, differentiated therapies that capitalise on the many advantages of the SonoTran Platform.

Therapeutics / Indication	Pre-clinical	First-in-man Trial
SonoTran + Therapeutic Ab mCRC	100	Commencement 2020
SonoTran + Anti PD-L1 Solid Tumours	100	Available for partnering
SonoTran + Oncolytic Virus Solid Tumours	100	Available for partnering
SonoTran + Anti-PD1 Combo Solid Tumours	100	Available for partnering
SonoTran + Small Molecule Pancreatic Ductal Adenocarcinoma	50

Evidence: Preclinical Data

SonoTran has been shown to enhance the delivery of multiple oncology agents spanning multiple drug classes, resulting in a significant enhancement of tumour retardation when compared to the oncology agents alone.

Example 1: Checkpoint Inhibitor anti-PD-L1

SonoTran has been shown to enhance the delivery of anti-PD-L1 in a preclinical murine model. Ten days after tumour implantation, the SonoTran Therapy Group received anti-PD-L1 (IV injection) together with SonoTran. Similarly the ‘Control Group’ received anti-PD-L1 ten days after tumour implantation. Eighteen days following anti-PD-L1 administration, four out of five animals in the SonoTran Therapy Group exhibited significant tumour retardation versus the Control Group animals. By day twenty eight this culminated in four out of five animals surviving in the SonoTran Therapy Group compared with no survivors in the Control Group.

Example 2: Oncolytic Vaccinia Virus (Myers et al)

SonoTran enhanced the delivery of an oncolytic vaccinia virus by a factor of 50-fold in a murine model (measuring luminescence of the reporter gene expression and corroborated by qPCR) one day post IV injection. This 50-fold enhancement resulted in a 10,000-fold increase vaccinia virus activity by day six. Moreover, improved delivery resulted in significantly enhanced tumour retardation in four out of four animals in the SonoTran treatment group, compared to only one out of four animals in the control group.